Odronextamab BLA Is Under Priority Review for 2 Lymphoma Indications
The FDA has granted priority review to odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.
Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia
In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.
Bosutinib Is Approved for Pediatric Ph+ CP–Chronic Myeloid Leukemia
The FDA has approved bosutinib to treat pediatric patients with Philadelphia chromosome–positive, chronic-phase chronic myelogenous leukemia.
Interim PET2 Scans May Be Redundant in Frontline Brentuximab Vedotin Regimens Treatments for Hodgkin Lymphoma
Data suggest that frontline treatment brentuximab vedotin elicits superior outcomes in patients with Hodgkin Lymphoma, regardless of PET2 results.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512